OCULAR THERAPEUTIX, INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M |
| Cost of revenue | $6.6M | $5.6M | $5.3M | $4.5M | $4.4M |
| Cash from operations | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M |
| Capital expenditure | $12.0M | $1.3M | $6.1M | $3.7M | $1.2M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M |
Shares outstanding 219.0M · Free float 90.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.